|Davidson's principles and practice of medicine|
NR Colledge, BR Walker, SH Ralston
Churchill Livingstone/Elsevier, 2010
|Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers|
R Plummer, G Attard, S Pacey, L Li, A Razak, R Perrett, M Barrett, ...
Clinical cancer research 13 (20), 6187-6194, 2007
|Davidson's principles and practice of medicine e-book: With STUDENT CONSULT Online Access|
BR Walker, NR Colledge
Elsevier Health Sciences, 2013
|Nasopharyngeal carcinoma: the next challenges|
ARA Razak, LL Siu, FF Liu, E Ito, B O’Sullivan, K Chan
European journal of cancer 46 (11), 1967-1978, 2010
|Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study|
HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ...
J Clin Oncol 35 (34), 3851-3858, 2017
|Inspiratory flow limitation during sleep in pre-eclampsia: comparison with normal pregnant and nonpregnant women|
G Connolly, ARA Razak, A Hayanga, A Russell, P McKenna, ...
European Respiratory Journal 18 (4), 672-676, 2001
|A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors|
TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen
Annals of Oncology 26 (9), 1824-1829, 2015
|Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial|
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 109, 2016
|First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors|
ARA Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, AF Shields, ...
Journal of clinical oncology 34 (34), 4142, 2016
|Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status|
SH Huang, JN Waldron, M Milosevic, X Shen, J Ringash, J Su, L Tong, ...
Cancer 121 (4), 545-555, 2015
|A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck|
AR Abdul Razak, D Soulieres, SA Laurie, SJ Hotte, S Singh, E Winquist, ...
Annals of oncology 24 (3), 761-769, 2012
|Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status|
SH Huang, B O'Sullivan, W Xu, H Zhao, D Chen, J Ringash, A Hope, ...
International Journal of Radiation Oncology* Biology* Physics 87 (5), 1078-1085, 2013
|Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care|
FA Miller, RZ Hayeems, JP Bytautas, PL Bedard, S Ernst, H Hirte, S Hotte, ...
European Journal of Human Genetics 22 (3), 391, 2014
|Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors|
S Leijen, RMJM van Geel, AC Pavlick, R Tibes, L Rosen, ARA Razak, ...
Journal of Clinical Oncology 34 (36), 4371-4380, 2016
|Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer|
HK Gan, LJ Bernstein, J Brown, J Ringash, M Vakilha, L Wang, ...
International Journal of Radiation Oncology* Biology* Physics 81 (1), 126-134, 2011
|T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 …|
PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ...
Journal of Clinical Oncology 37 (4), 318-327, 2019
|Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials|
A Manji, I Brana, E Amir, G Tomlinson, IF Tannock, PL Bedard, A Oza, ...
J Clin Oncol 31 (33), 4260-4267, 2013
|Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma|
MM Gounder, A Zer, WD Tap, S Salah, MA Dickson, AA Gupta, ...
Journal of Clinical Oncology 34 (26), 3166, 2016
|Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma|
BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ...
PLoS One 12 (12), e0189848, 2017
|A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)|
S Richter, PL Bedard, EX Chen, BA Clarke, B Tran, SJ Hotte, A Stathis, ...
Investigational new drugs 32 (2), 243-249, 2014